5 hours NTLA Begins Phase III Study on Hereditary Angioedema Candidate Zacks
Intellia starts the pivotal phase III HAELO study on NTLA-2002 for the treatment of hereditary angioedema (HAE).
Intellia starts the pivotal phase III HAELO study on NTLA-2002 for the treatment of hereditary angioedema (HAE).